Clinical Trials Logo

Hyperparathyroidism, Secondary clinical trials

View clinical trials related to Hyperparathyroidism, Secondary.

Filter by:

NCT ID: NCT01785849 Completed - Clinical trials for Hyperparathyroidism, Secondary

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis

Start date: March 12, 2013
Phase: Phase 3
Study type: Interventional

This study is designed to assess the efficacy and safety of etelcalcetide compared with placebo in the treatment of SHPT in patients with chronic kidney disease (CKD) receiving hemodialysis.

NCT ID: NCT01741064 Completed - Clinical trials for Secondary Hyperparathyroidism

Morbidity Related to Secondary Hyperparathyroidism After Renal Transplantation

SHPT-RT
Start date: February 2012
Phase: N/A
Study type: Observational

The purpose of the study is to evaluate the long term vascular morbidity and mortality in kidney transplant recipients based on one year post transplant levels of intact parathyroid hormone.

NCT ID: NCT01725113 Terminated - Kidney Failure Clinical Trials

Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol

ECRIP
Start date: November 2012
Phase: Phase 4
Study type: Interventional

The purpose of this non-inferiority study is to compare the safety and effectiveness of a mineral and bone disease treatment protocol based on calcitriol to one based on paricalcitol in hemodialysis patients using revised Kidney Disease: Improving Global Outcomes (KDIGO) parathyroid hormone targets.

NCT ID: NCT01704079 Completed - Clinical trials for Chronic Kidney Disease

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

Start date: November 2012
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated

NCT ID: NCT01653379 Completed - Clinical trials for Secondary Hyperparathyroidism

A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism

Start date: August 2012
Phase: Phase 2
Study type: Interventional

This is an open-label, dose-ranging study of the vitamin D analog DP001 in patients with end-stage renal disease (ESRD). The primary goals of this 4-week Phase 2A study are to identify an appropriate starting dose of DP001 to be used in subsequent studies in this population and for evaluation of pharmacokinetics of DP001 in ESRD patients.

NCT ID: NCT01651000 Completed - Clinical trials for Chronic Kidney Disease

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

Start date: September 2012
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated

NCT ID: NCT01640184 Completed - Hyperparathyroidism Clinical Trials

Efficacy and Safety of Ultrasonic Ablation to Treat Secondary Hyperparathyroidism in Chronic Kidney Disease Patients

Start date: August 2012
Phase: N/A
Study type: Interventional

It is difficulty for the treatment of secondary hyperparathyroidism in the chronic kidney disease (CKD) patients who had not succeeded medical therapy and could not get parathyroidectomy. The investigators suppose that ultrasonic ablation may be a valuable alternative treatment that help control secondary hyperparathyroidism in CKD patients presenting with enlarged parathyroid gland(s) visible at ultrasonography.

NCT ID: NCT01576146 Terminated - Clinical trials for Secondary Hyperparathyroidism

Open-label Study to Assess the Long-term Safety and Efficacy of AMG 416 (Also Known as KAI-4169) in Patients With Secondary Hyperparathyroidism

Start date: March 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the long term safety and efficacy of thrice weekly intravenous (IV) administration of KAI-4169 in the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis subjects.

NCT ID: NCT01506947 Completed - Clinical trials for Stage 5 Chronic Kidney Diseases

A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients

Start date: May 10, 2012
Phase: Phase 4
Study type: Interventional

To evaluate the effect of PTH lowering on erythropoietin consumption in calcitriol-resistant patients with stage 5 chronic kidney disease.

NCT ID: NCT01479088 Recruiting - Clinical trials for Secondary Hyperparathyroidism

Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD)

Start date: March 2010
Phase: Phase 2/Phase 3
Study type: Interventional

Twelve-month, multicenter, intra-subject controlled (retrospective-prospective), open-label, active-treatment study to evaluate the dose-response and pharmacokinetics (PK) of cinacalcet HCl for the treatment of Secondary Hyperparathyroidism (SHPT) in paediatric subjects with chronic kidney disease (CKD) on dialysis, followed by 12-month study extension.